Clinical Trial Update: Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 clinical trial evaluating autologous CD19-CD22 targeted T cells in patients with refractory or relapsed central nervous system lymphoma, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• CD19-CD22 targeted T cells

Snippet

Sponsor: Hrain Biotechnology Co., Ltd. | Conditions: Central Nervous System Lymphoma | EARLY_Phase 1 | Status: RECRUITING